Marinobufagenin, left ventricular geometry and cardiac dysfunction in end-stage kidney disease patients

[1]  C. Indolfi,et al.  Altered circulating marinobufagenin levels and recurrent intradialytic hypotensive episodes in chronic hemodialysis patients: a pilot, prospective study. , 2021, Reviews in cardiovascular medicine.

[2]  G. Piecha,et al.  Endogenous Mammalian Cardiotonic Steroids—A New Cardiovascular Risk Factor?—A Mini-Review , 2021, Life.

[3]  Kartheek Garikapati,et al.  Uraemic Cardiomyopathy: A Review of Current Literature , 2021, Clinical Medicine Insights. Cardiology.

[4]  O. Fedorova,et al.  The Cardiotonic Steroid Marinobufagenin Is a Predictor of Increased Left Ventricular Mass in Obesity: The African-PREDICT Study , 2020, Nutrients.

[5]  D. Pavlovic.  Endogenous cardiotonic steroids and cardiovascular disease, where to next? , 2019, Cell calcium.

[6]  W. März,et al.  The endogenous cardiotonic steroid Marinobufagenin and decline in estimated glomerular filtration rate at follow-up in patients with arterial hypertension , 2019, PloS one.

[7]  A. Więcek,et al.  Plasma marinobufagenin immunoreactivity in patients with chronic kidney disease: a case control study. , 2018, American journal of physiology. Renal physiology.

[8]  R. D. de Paula,et al.  Uremic Cardiomyopathy: A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle , 2018, Front. Med..

[9]  O. Fedorova,et al.  Marinobufagenin and left ventricular mass in young adults: The African-PREDICT study , 2018, European journal of preventive cardiology.

[10]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, European heart journal cardiovascular Imaging.

[11]  Patrizio Lancellotti,et al.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2016, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[12]  Simon Gibbs,et al.  2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.

[13]  O. Kamp,et al.  Eccentric Left Ventricular Hypertrophy and Sudden Death in Patients with End-Stage Kidney Disease , 2015, American Journal of Nephrology.

[14]  J. Gottdiener,et al.  Recommendationsontheuseofechocardiography in adult hypertension : a report from the European Association of Cardiovascular Imaging ( EACVI ) and the American Society of Echocardiography ( ASE ) † , 2015 .

[15]  W. Tang,et al.  Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure , 2015, Circulation. Heart failure.

[16]  Victor Mor-Avi,et al.  Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. , 2015, European heart journal cardiovascular Imaging.

[17]  Simon Gibbs,et al.  [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.

[18]  J. Lingrel,et al.  Reduction of Na/K-ATPase Potentiates Marinobufagenin-induced Cardiac Dysfunction and Myocyte Apoptosis* , 2012, The Journal of Biological Chemistry.

[19]  J. Shapiro,et al.  Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets , 2009, Pharmacological Reviews.

[20]  C. Zoccali,et al.  Endogenous ouabain and cardiomyopathy in dialysis patients , 2008, Journal of internal medicine.

[21]  G. Scheiner-Bobis,et al.  Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth. , 2007, American journal of physiology. Cell physiology.

[22]  P. Rizzon,et al.  Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy , 2006, European journal of heart failure.

[23]  P. Manunta,et al.  Salt intake and depletion increase circulating levels of endogenous ouabain in normal men. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[24]  Deepak Malhotra,et al.  Central Role for the Cardiotonic Steroid Marinobufagenin in the Pathogenesis of Experimental Uremic Cardiomyopathy , 2006, Hypertension.

[25]  C. Zoccali,et al.  Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. , 2004, Kidney international.

[26]  E. Lakatta,et al.  Marinobufagenin, an endogenous ligand of alpha-1 sodium pump, is a marker of congestive heart failure severity , 2002, Journal of hypertension.

[27]  A. Askari,et al.  Involvement of Src and epidermal growth factor receptor in the signal-transducing function of Na+/K+-ATPase. , 2000, The Journal of biological chemistry.

[28]  J. Shapiro,et al.  Intracellular Reactive Oxygen Species Mediate the Linkage of Na+/K+-ATPase to Hypertrophy and Its Marker Genes in Cardiac Myocytes* , 1999, The Journal of Biological Chemistry.

[29]  B. Kahn,et al.  Multiple Signal Transduction Pathways Link Na+/K+-ATPase to Growth-related Genes in Cardiac Myocytes , 1998, The Journal of Biological Chemistry.

[30]  P. Parfrey,et al.  The clinical course of left ventricular hypertrophy in dialysis patients. , 1990, Nephron.

[31]  T. Pryor,et al.  Evaluation of size and dynamics of the inferior vena cava as an index of right-sided cardiac function. , 1984, The American journal of cardiology.